Percheron Therapeutics Secures $2.2M to Fuel HMBD-002 Phase II Progress
Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.
- Completed 2 for 5 entitlement offer raising $2.2 million
- Funds to support HMBD-002 phase II trial planned for 2026
- Includes new shares and free attaching options exercisable at $0.01
- Strong participation from existing and new shareholders
- Upcoming presentations at major oncology conferences
Capital Raise Positions Percheron for Clinical Advancement
Percheron Therapeutics (ASX:PER) has successfully raised approximately $2.2 million through a 2 for 5 non-renounceable entitlement offer, a key step in advancing its lead immuno-oncology asset HMBD-002 towards a phase II clinical trial slated for later this year. The capital injection combines $0.8 million from existing shareholders with $1.4 million from new investors, reflecting robust market appetite for the company’s novel monoclonal antibody targeting the immune checkpoint regulator VISTA.
The offer included free attaching unlisted options exercisable at $0.01 each, valid for two years, sweetening the deal for participants. This structure aligns with Percheron’s strategy to extend shareholder value while securing funds to progress clinical development and working capital needs.
Backing the Next Phase of HMBD-002 Development
Chair Dr Charmaine Gittleson emphasised the significance of the capital raise, noting that it leaves the company well positioned to advance HMBD-002. The phase I trial has already demonstrated the drug’s safety and tolerability in patients with advanced cancers, setting the stage for the upcoming phase II study.
The company’s plans are ambitious: a modular, multi-arm phase II trial designed to explore HMBD-002’s efficacy across several tumour types. This approach was outlined earlier this year and reflects a growing trend in oncology drug development to maximise data generation and patient benefit simultaneously. The entitlement offer’s success builds on this momentum, providing the financial runway needed to initiate these trials in calendar year 2026.
Percheron’s recent capital raise follows a period of strategic focus and financial discipline, including a 64% reduction in half-year losses reported in February, driven by the pivot to HMBD-002 after discontinuing less promising assets. The company’s cash reserves and fresh capital now underpin its clinical ambitions more securely.
Upcoming Data Presentations at Leading Oncology Conferences
These presentations offer important visibility for Percheron’s pipeline and could influence investor sentiment as the company moves closer to pivotal clinical milestones. The timing of these conferences, shortly after the capital raise, suggests a coordinated effort to maintain engagement with both scientific and investment communities.
Percheron’s capital raise and clinical progress should be viewed in light of its earlier announcement of the entitlement offer terms, which offered shares at a 20% discount and included free options, a package designed to attract participation from both existing and new shareholders. This well-received offer is a tangible sign of confidence in HMBD-002’s potential and the company’s clinical strategy.
Bottom Line?
Percheron’s $2.2 million raise clears a crucial financial hurdle, but the market will soon pivot to clinical data readouts and trial initiation timelines to gauge real momentum.
Questions in the middle?
- Will the phase II trial design capture sufficient efficacy signals to justify further investment?
- How will upcoming data presentations influence institutional interest and share liquidity?
- What is the anticipated timeline and budget for HMBD-002’s transition from phase II to potential registration studies?
